Lomustine Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 10 mg, 40 mg, 100 mg
Reference Brands: Gleostine (USA)
Category:
Oncology Cancer Care
Lomustine is available in Capsules
and strengths such as 10 mg, 40 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lomustine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lomustine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lomustine is a nitrosourea alkylating agent with potent antineoplastic activity, widely used in chemotherapy protocols for the treatment of various malignancies. It works by alkylating and crosslinking DNA, which leads to inhibition of DNA and RNA synthesis and ultimately results in cancer cell death. In addition, lomustine carbamoylates DNA and cellular proteins, further disrupting RNA processing and impairing tumor cell replication.
Lomustine is a highly lipophilic compound, allowing it to effectively cross the blood–brain barrier. This unique pharmacokinetic property makes it particularly valuable in the treatment of primary and metastatic brain tumors, where many anticancer agents have limited penetration. It is most commonly used in the management of brain tumors and is also employed as a second-line treatment option for Hodgkin lymphoma, especially in cases where standard therapies have failed.
Internationally known by the abbreviation CCNU, lomustine was originally marketed under the brand name CeeNU and is currently available as Gleostine in regulated markets. Due to its strong cytotoxic activity, lomustine is administered under strict medical supervision as part of carefully monitored chemotherapy regimens.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing